©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 8, 2015; 7(28): 2829-2833
Published online Dec 8, 2015. doi: 10.4254/wjh.v7.i28.2829
Published online Dec 8, 2015. doi: 10.4254/wjh.v7.i28.2829
Update on hepatitis C: Direct-acting antivirals
Leon L Seifert, Department of Transplantation Medicine, University Hospital Münster, 48149 Münster, Germany
Ryan B Perumpail, Aijaz Ahmed, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, United States
Author contributions: Seifert LL, Perumpail RB and Ahmed A designed research and analyzed data; Seifert LL performed research and wrote the paper.
Conflict-of-interest statement: We declare that we have no conflicts of interest.
Correspondence to: Aijaz Ahmed, MD, Associate Professor of Medicine, Medical Director Liver Transplant Program, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 750 Welch Road, Suite 210, Stanford, CA 94305, United States. aijazahmed@stanford.edu
Telephone: +1-650-4986091 Fax: +1-650-4985692
Received: July 20, 2015
Peer-review started: July 24, 2015
First decision: October 22, 2015
Revised: October 24, 2015
Accepted: November 23, 2015
Article in press: November 25, 2015
Published online: December 8, 2015
Processing time: 136 Days and 16.6 Hours
Peer-review started: July 24, 2015
First decision: October 22, 2015
Revised: October 24, 2015
Accepted: November 23, 2015
Article in press: November 25, 2015
Published online: December 8, 2015
Processing time: 136 Days and 16.6 Hours
Core Tip
Core tip: Recently, several direct-acting antivirals (DAAs) have been approved for treatment of hepatitis C virus (HCV)-infected patients and to help combat the virus. These drugs have revolutionized the management of HCV as all-oral regimens with favorable side effect profiles and superior rates of sustained virological response. Emerging real-world data are demonstrating results comparable to registration trials for DAA agents. Suddenly, the potential for eradicating HCV is on the horizon.